The current research
involves the synthesis of a new Schiff base
through the reaction between 2-chlorobenzaldehyde and 3,3′-dimethyl-[1,1′-biphenyl]-4,4′-diamine
by using a natural acid catalyst and a synthesized compound physicochemically
characterized by X-ray diffraction, Fourier transform infrared spectroscopy, 1H- and 13C-nuclear magnetic resonance, and liquid
chromatography–mass spectrometry. Thermal studies were conducted
using thermogravimetric, differential thermal analysis, and differential
thermogravimetric curves. These curves were obtained in an inert nitrogen
environment from ambient temperature to 1263 K using heating rates
of 10, 15, and 20 K·min–1. Using thermocurve
data, model-free isoconversional techniques such as Kissinger–Akahira–Sunose,
Flynn–Wall–Ozawa, and Friedman are used to determine
kinetic parameters. These parameters include activation energy, phonon
frequency factor, activation enthalpy, activation entropy, and Gibb’s
free energy change. All of the results have been thoroughly investigated.
The molecule’s anti-inflammatory and antidiabetic properties
were also examined. To learn more about the potential of the Schiff
base and how successfully it can suppress the amylase enzyme, a molecular
docking experiment was also conducted. For in silico research, the Swiss Absorption, Distribution, Metabolism, Excretion,
and Toxicity algorithms were used to calculate the theoretical pharmacokinetic
properties, oral bioavailability, toxic effects, and biological activities
of the synthesized molecule. Moreover, the cytotoxicity tests against
a human lung cancer cell line (A549) using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide assay demonstrated that the synthesized Schiff base exhibited
significant anticancer properties.